included in the study. The proportion of hypothyroidism amongst GCA patients was increased in comparison with controls (18.2% vs. 6.91%, respectively, p-value <0.001) , as was hyperthyroidism (2. 56% and 1.19% respectively, pvalue <0.001) . After controlling for confounders, GCA demonstrated a robust independent association with hypothyroidism on multivariate logistic regression (OR 1.297, 95% CI 1.187-1.418, Table 1 ). In contrast, when a similar model was performed in order to assess the nature of the association between GCA and hyperthyroidism, it was found to be non-significant, with an OR of 1.097. Background: Behcet's disease is a multisystemic chronic relapsing inflammatory disease, classified among the vasculitides. The aetiology of Behcet's disease is unknown. Several cytokines, among them TNF-α, are involved in the pathogenesis of the disease. Objectives: We aimed to assess efficacy and safety of Adalimumab (ADA) in patients with active Behcet's arthritis not responding to one or more DMARDS and to assess the impact of treatment on the cytokine milieu. Methods: Eligible patients (pts) with active arthritis were enrolled in a 24 weeks single center prospective open-label study. Pts who relapsed within 12 weeks following ADA discontinuation could enter a 3 year extension study. The efficacy was assessed by 68 tender and 66 swollen joint count, patient visual analogue scale (VAS) for pain, physician overall disease activity VAS, health assessment questionnaire (HAQ), Behçet's Disease Current Activity Form (BDCAF), C reactive protein (CRP) and erythrocyte sedimentation rate (ESR). TNF-α,IL-1β, IL-6, INF-γ, IL-10 and IL-17a were evaluated at baseline, after 24 and 48 weeks of treatment, by ProcartaPlex Human High Sensitivity -Immunoassay kit. Trough ADA serum levels and anti-drug antibodies were measured at baseline, week 24 and 48. Results: Ten pts (6 females),age (mean, standard deviation -SD) 45 (8.4) years, with a disease duration of 11.6 (10) years, were enrolled and treated with subcutaneous ADA 40mg every 2 weeks for 24 weeks. The results are described Abstract THU0344 - Background: Giant Cell Arteritis (GCA) is a medical emergency requiring prompt and appropriate management to prevent complications. The British Society of Rheumatology (BSR) has set out guidelines on the appropriate management of suspected GCA targeting both primary and secondary-care physicians. Hospitals increasingly use care-pathways to facilitate appropriate initial management of GCA by non-rheumatologists. Evidence is limited, however, on the impact of such interventions on patient care. Objectives: To evaluate the impact of designing a GCA care-pathway for nonrheumatologists (acute and general physicians) on patient care in terms of: (i) duration from referral to temporal artery biopsy (TAB) and rheumatology review; (ii) glucocorticoid therapy burden; and (iii) proportion of referrals with a final diagnosis of GCA Methods: We performed a retrospective study of all patients diagnosed with GCA between 3 periods: prior to introducing a GCA pathway (2007 ( -2009 ( ), rheumatology led GCA pathway (2010 ( -2012 , and non-rheumatology led GCA pathway (2012) (2013) (2014) (2015) (2016) . We identified patients from a TAB database and collected general demographic data, initiation of glucocorticoid therapy, referral for TAB and rheumatology clinic, date of TAB and clinic review, biopsy findings, and final diagnosis. Results: Table 1 summarises the main findings. After introducing the rheumatology-led pathway (2010) (2011) (2012) , rate of referrals for TAB per month declined to 0.78, the proportion of patients having a TAB within 14 days of referral reached 100%, and the proportion of patients with a positive biopsy increased to 30% suggesting appropriate use of the pathway and an improvement in care. However introducing a non-rheumatology led GCA pathway (2012) (2013) (2014) (2015) (2016) , led to increased referral numbers. The proportion of TAB within 14 days decreased, and the proportion with a positive biopsy declined (17%).
